Abstract
Abstract Background Aortic aneurysm occurs in the thoracic and abdominal sections of the aorta and is a deadly late-age-at-onset disease. Thoracic aortic aneurysms (TTAs) are characterized by progressive smooth muscle cell rarefaction due to impaired extracellular matrix. The aim of this study was to investigate fibrillin-1 (FBN-1), fibronectin-1 (FN-1) and tissue inhibitors of metalloproteinases-3 (TIMP-3) gene expression levels in patients with TTA. Materials and methods The data were analyzed for 16 patients treated for TAA and nine control subjects. Tissue samples obtained during surgery were frozen immediately in liquid nitrogen and stored at −80°C until RNA isolation. Gene expression analysis was performed by quantitative reverse transcription polymerase chain reaction for each gene and Beta actin was used as control gene. 2−ΔΔCT method was used for the determining expression levels of the genes. Results According to the results of this study, TIMP-3 gene was nine-fold higher expressed in TAA tissues (p = 0.034). Furthermore, TIMP-3 expression levels were found associated with fasting blood glucose, red blood cells and ejection fraction. The gene expression levels of FBN-1 and FN-1 were not statistically significant (p > 0.05). Conclusion In this clinical trial, we concluded that TIMP-3 expression increases in dilated aorta.
Highlights
Aortic aneurysms are characterized by abnormal aortic enlargement resulting from a large scale or limited weakening of the vessel wall
The ascending thoracic aortic aneurysm (TTA) is associated with various syndromic conditions such as hypertension, bicuspid aortic valve (BAV) and Marfan syndrome (MFS) and causes Torasik Aort Anevrizma (TAA) dissection leading to early life stage mortality [7]
The results were evaluated as TTA
Summary
Aortic aneurysms are characterized by abnormal aortic enlargement resulting from a large scale or limited weakening of the vessel wall. This formation is derived from defects in the synthesis of extracellular matrix (ECM) proteins or the accelerated degradation of the vascular ECM [1, 2]. The aim of this study was to investigate fibrillin-1 (FBN-1), fibronectin-1 (FN-1) and tissue inhibitors of metalloproteinases-3 (TIMP3) gene expression levels in patients with TTA. Results: According to the results of this study, TIMP-3 gene was nine-fold higher expressed in TAA tissues (p = 0.034).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
